Choosing the Right Protocol to Establish MCF-7 Tumor Xenograft in Nude Mice

Author:

Hosseinimehr Seyed Jalal1ORCID,Behzadi Ramezan23,Ahmadpour Sajjad4ORCID,Amiri Fereshteh Talebpour5,Kavosian Saeid2,Asori Mohsen2

Affiliation:

1. Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran

2. North Research Center, Pasteur Institute of Iran, Amol, Iran, Qom University of Medical Science and Health Services

3. Department of Biology, Faculty of Sciences, Islamic Azad University Science and Research Branch, Tehran, Iran

4. Gastroenterology and Hepatology Diseases Research Center, Qom University of Medical Sciences, Qom, Iran

5. Department of Anatomy, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Abstract

Background: Xenografts of various human cancers in nude mice provide a helpful model in cancer research. This study aimed to develop a xenograft mouse model of MCF-7 breast cancer using injectable estradiol valerate. Methods: Thirty healthy female C57 nu/nu mice were engrafted with three protocols to establish an MCF-7 tumor. Injectable estradiol valerate (10 mg/ml) was used as a substitute for estradiol pellets. The development of tumors was recorded daily, and data were statistically analyzed. Histology of bladder, kidney, and tumors was used to estimate tumor establishment and probable urinary adverse effects. Results: According to the findings, the duration of MCF-7 tumor growth was the lowest for protocol B (tumor tissue). Also, this protocol had the highest xenograft yield within the shortest time duration (37 days for protocol B vs. 73 days for protocol A) without causing urinary adverse effects. Conclusion: Our findings revealed that estradiol valerate, which is way less expensive than estradiol pellets, can be used as a tumor proliferator to establish MCF-7 tumors with the highest yield when MCF-7 tumors have been used for xenograft.

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Pharmacology,Molecular Medicine

Reference23 articles.

1. Li Y.; Mi C.; Wu Y.Z.; Yang S.F.; Yang Z.Q.; The effects of genistein on epidermal growth factor receptor mediated signal transduction pathway in human ovarian carcinoma cells lines SKOV3 and its xenograft in nude mice. Chin J Pathol 2004,33(6),546-549

2. Fulzele S.V.; Chatterjee A.; Shaik M.S.; Jackson T.; Ichite N.; Singh M.; 15-Deoxy-Delta12,14-prostaglandin J2 enhanc-es docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs 2007,18(1),65-78

3. Fleming J.M.; Miller T.C.; Meyer M.J.; Ginsburg E.; Vonderhaar B.K.; Local regulation of human breast xenograft models. J Cell Physiol 2010,224(3),795-806

4. Jung J.; Human tumor xenograft models for preclinical as-sessment of anticancer drug development. Toxicol Res 2014,30(1),1-5

5. Holliday D.L.; Speirs V.; Choosing the right cell line for breast cancer research. Breast Cancer Res 2011,13(4),215

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3